{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:03:42Z","timestamp":1790337822948,"version":"4.1.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med."],"abstract":"<jats:p>Alternative splicing and alternative promoters generate splicing variants to expand proteomic and transcriptional diversity to orchestrate physiological activities and dictate tumorigenesis. Splicing variants are attractive tumor-associated antigens (TAAs) for the clinical development of cancer therapies. Here, recent progress in claudin-18 isoform 2 (CLDN18.2)- and fibroblast growth factor receptor 2 isoform b (FGFR2b)-targeted therapeutics is summarized, and perspectives in this field are discussed. Zolbetuximab and bemarituzumab are first-generation monoclonal antibodies (mAbs) targeting CLDN18.2 and FGFR2b, respectively, while next-generation biologics targeting these TAAs are emerging. Single-agent objective response rates of CLDN18.2-targeting mAb (omectatug), antibody\u2013drug conjugates (ADCs, arcotatug tavatecan, BL-M05D1, garetatug rezetecan, JS107, sonesitatug vedotin and tecotabart vedotin), bispecific antibodies (emaretamig and givastomig) and chimeric antigen receptor T (CAR-T) cells (IMC002) were higher than that of zolbetuximab. Gastrointestinal toxicity, nausea and vomiting are common on-target\/off-tumor adverse effects of CLDN18.2-targeted biologics, which are mitigated for arcotatug tavatecan and givastomig as a result of antibody engineering. Combination therapy of zolbetuximab plus chemotherapy is approved for the treatment of gastric and gastroesophageal junction cancer patients, while results of other CLDN18.2-targeting biologics in phase 3 clinical trials are anticipated with expectations for improved clinical activities and mitigated adverse events. Diagnostics detecting alternative isoforms and combination strategies using immune checkpoint inhibitors would address resistance mechanisms, such as epitope-losing isoform switching and immune evasion. Comparative studies on ADC monotherapy versus combination mAb-chemotherapy as well as the clinical development of bispecific ADCs and allogeneic CAR-T cells should further improve the clinical benefits of CLDN18.2- and FGFR2b-targeted therapies.<\/jats:p>","DOI":"10.3389\/fmmed.2026.1927389","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:47:42Z","timestamp":1790336862000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy"],"prefix":"10.3389","volume":"6","author":[{"given":"Masuko","family":"Katoh","sequence":"first","affiliation":[{"name":"Department of Global Network, M & M Precision Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Global Network, M & M Precision Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1538-7445.AM2024-2535","article-title":"Development of claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-claudin 18.2 monoclonal antibody osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma","volume":"84","author":"Alderson","year":"2024","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1158\/1538-7445.AM2026-6944","article-title":"Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity","volume":"86","author":"An","year":"2026","journal-title":"Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115808","DOI":"10.1016\/j.ejca.2025.115808","article-title":"Tecotabart vedotin in claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial","volume":"230","author":"Bai","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","article-title":"Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer - implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.3390\/curroncol31120572","article-title":"Canadian consensus recommendations for predictive biomarker testing in gastric and gastroesophageal junction adenocarcinoma","volume":"31","author":"Brezden-Masley","year":"2024","journal-title":"Curr. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-Selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2026.44.16_suppl.3030","article-title":"Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2\u2013expressing solid tumors","volume":"44","author":"Cheng","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.cell.2026.04.016","article-title":"Navigating the clinical progress of antibody-drug conjugates: emerging opportunities and remaining challenges","volume":"189","author":"Conilh","year":"2026","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2453515","DOI":"10.1080\/19420862.2025.2453515","article-title":"With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","article-title":"Fibroblasts as immune regulators in infection, inflammation and cancer","volume":"21","author":"Davidson","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101599","DOI":"10.1016\/j.lanepe.2026.101599","article-title":"Evolution of bispecific and multispecific antibodies in cancer therapy","volume":"64","author":"Fontana","year":"2026","journal-title":"Lancet Reg. Health Eur."},{"key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e15019","DOI":"10.1200\/JCO.2024.42.16_suppl.e15019","article-title":"SCR-A002, a novel FGFR2b-targeting antibody-drug-conjugate for solid tumors","volume":"42","author":"Fu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e006704","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"LB268","DOI":"10.1158\/1538-7445.AM2026-LB268","article-title":"Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers","volume":"86","author":"Gao","year":"2026","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e011857","DOI":"10.1136\/jitc-2025-011857","article-title":"An affinity-modulated T cell engager targeting claudin 18.2 shows potent anti-tumor activity with limited cytokine release","volume":"13","author":"Gaspar","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2026.44.16_suppl.4037","article-title":"A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2\/4-1BB bispecific antibody, in patients with advanced solid tumors","volume":"44","author":"Gou","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41580-026-00978-w","article-title":"Tight junction structure, assembly and (dys)function","volume":"27","author":"G\u00fcnzel","year":"2026","journal-title":"Nat. Rev. Mol. Cell Biol. Epub Ahead Print"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2024.42.16_suppl.2662","article-title":"First-in-human phase I\/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors","volume":"42","author":"Guo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/s41588-022-01190-0","article-title":"Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH","volume":"54","author":"Hung","year":"2022","journal-title":"Nat. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2024-CT132","article-title":"A phase I\/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors","volume":"84","author":"Janjigian","year":"2024","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(20)30460-5","article-title":"Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study","volume":"21","author":"Jin","year":"2020","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1042\/EBC20220016","article-title":"WNT signaling and cancer stemness","volume":"66","author":"Katoh","year":"2022","journal-title":"Essays Biochem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer","volume":"54","author":"Katoh","year":"2024","journal-title":"Int. J. Mol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1736","DOI":"10.1002\/ctm2.1736","article-title":"Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours","volume":"14","author":"Katoh","year":"","journal-title":"Clin. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1661016","DOI":"10.3389\/fmmed.2025.1661016","article-title":"Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules","volume":"5","author":"Katoh","year":"2025","journal-title":"Front. Mol. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41573-024-01025-z","article-title":"Protein isoform-centric therapeutics: expanding targets and increasing specificity","volume":"23","author":"Kjer-Hansen","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","article-title":"A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-Positive advanced or metastatic solid tumors","volume":"31","author":"Ku","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"676781","DOI":"10.3389\/fonc.2021.676781","article-title":"Context-dependent roles of claudins in tumorigenesis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1538-7445.AM2022-4260","article-title":"PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody constructed with the PACbody and SPECpair technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2026.44.2_suppl.398","article-title":"Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers","volume":"44","author":"Li","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12916-025-04597-8","article-title":"Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2\u00d7CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"24","author":"Li","year":"2026","journal-title":"BMC Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.2024.42.16_suppl.4049","article-title":"Safety and efficacy results from the phase I\/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+\/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"42","author":"Liu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"S903","DOI":"10.1016\/j.annonc.2024.08.1522","article-title":"First in human phase I\/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric\/gastroesophageal junction cancer","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1874","DOI":"10.1016\/j.annonc.2025.10.126","article-title":"First-line osemitamab plus nivolumab and CAPOX for advanced G\/GEJ cancer (TranStar102) \u2013 updated efficacy analysis of cohort G by CLDN18.2 and PD-L1 expression from a phase I\/II study","volume":"36","author":"Liu","year":"2025","journal-title":"Ann. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e16012","DOI":"10.1200\/JCO.2024.42.16_suppl.e16012","article-title":"Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors","volume":"42","author":"Luo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2025.43.4_suppl.456","article-title":"Safety and preliminary efficacy of ATG-022 in patients with advanced\/metastatic gastric cancer (CLINCH)","volume":"43","author":"Ma","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B58","doi-asserted-by":"publisher","first-page":"107698","DOI":"10.1016\/j.esmoop.2026.107698","article-title":"Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies","volume":"11","author":"Maron","year":"2026","journal-title":"ESMO Open"},{"key":"B59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41581-023-00731-y","article-title":"The role of claudins in homeostasis","volume":"19","author":"Meoli","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1136\/gutjnl-2015-309168","article-title":"Genetic variation and gastric cancer risk: a field synopsis and meta-analysis","volume":"64","author":"Mocellin","year":"2015","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41598-025-87944-2","article-title":"Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function","volume":"15","author":"Morey","year":"2025","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/jcp-2025-210328","article-title":"Claudin 18.2 in cancer research and treatment: a pathologist's perspective","volume":"79","author":"Murtazaalieva","year":"2026","journal-title":"J. Clin. Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"LB227","DOI":"10.1158\/1538-7445.AM2025-LB227","article-title":"ALK201, a first-in-class FGFR2b-targeting antibody-drug conjugate for patients with FGFR2b+ gastric cancer and other solid tumors","volume":"85","author":"Pan","year":"2025","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41577-026-01280-8","article-title":"Progress in the development of cytokine armoured CAR T cells","volume":"26","author":"Prasad","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.1016\/j.annonc.2025.08.1514","article-title":"A phase I trial of KD-496, a CLDN18.2\/NKG2D dual targeting CAR-T, in patients with gastrointestinal cancers","volume":"36","author":"Qi","year":"","journal-title":"Ann. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-Cell-Engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"S1620","DOI":"10.1016\/j.annonc.2025.09.092","article-title":"Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G\/GEJC): FORTITUDE-101 phase III study results","volume":"36","author":"Rha","year":"2025","journal-title":"Ann. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"","journal-title":"Lancet Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"","journal-title":"Nat. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2026.44.16","article-title":"First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors","volume":"44","author":"Ruan","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2026.44.2_suppl.709","article-title":"Phase 1\/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"44","author":"Saeed","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41568-026-00913-3","article-title":"Claudin proteins as emerging therapeutic targets for solid tumours","volume":"26","author":"Saviano","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"IA006","DOI":"10.1158\/1535-7163.TARG-23-IA006","article-title":"Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study","volume":"22","author":"Schram","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/cancers13071703","article-title":"Fibroblast growth factor receptor 2 isoforms detected via novel RNA ISH as predictive biomarkers for progestin therapy in atypical hyperplasia and low-grade endometrial cancer","volume":"13","author":"Sengal","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.1016\/j.annonc.2025.08.1515","article-title":"Updated efficacy of ASKB589 plus CAPOX\/PD-1 inhibitor in first - line metastatic G\/GEJ adenocarcinoma: Phase Ib\/II study","volume":"36","author":"Shen","year":"2025","journal-title":"Ann. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"S1121","DOI":"10.1016\/j.annonc.2025.08.2756","article-title":"ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, advanced solid tumors: phase I\/Ib trial","volume":"36","author":"Shitara","year":"","journal-title":"Ann. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","volume":"31","author":"Shitara","year":"","journal-title":"Nat. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41591-026-04306-9","article-title":"First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial","volume":"32","author":"Shitara","year":"2026","journal-title":"Nat. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s43018-022-00384-z","article-title":"Dysregulation and therapeutic targeting of RNA splicing in cancer","volume":"3","author":"Stanley","year":"2022","journal-title":"Nat. Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"100844","DOI":"10.1016\/j.modpat.2025.100844","article-title":"Analytical and clinical performance of the VENTANA CLDN18 (43-14A) RxDx assay in gastric and gastroesophageal junction adenocarcinoma tissue samples in SPOTLIGHT and GLOW","volume":"38","author":"Stratton","year":"2025","journal-title":"Mod. Pathol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.esmoop.2025.106053","article-title":"Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort","volume":"11","author":"Ter\u00e1n","year":"2026","journal-title":"ESMO Open"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A multicentre, phase 2a study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"T\u00fcreci","year":"2019","journal-title":"Ann. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.iotech.2023.100604","article-title":"A phase I clinical trial of QLS31905 in advanced solid tumors","volume":"20","author":"Wang","year":"","journal-title":"Immunooncol. Technol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","article-title":"Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors","volume":"41","author":"Wang","year":"","journal-title":"J. Clin. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","article-title":"ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing","volume":"33","author":"Warzecha","year":"2009","journal-title":"Mol. Cell"},{"key":"B97","doi-asserted-by":"publisher","first-page":"A1368","DOI":"10.1136\/jitc-2025-SITC2025.1202","article-title":"Rapid discovery and development of antibodies that provoke macrophages to eliminate gastroesophageal cancer","volume":"13","author":"Wienclaw","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e1981202","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MABS"},{"key":"B99","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.2022.40.16_suppl.4030","article-title":"Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1158\/1538-7445.AM2025-3778","article-title":"Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer","volume":"85","author":"Xu","year":"2025","journal-title":"Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"CT010","DOI":"10.1158\/1538-7445.AM2025-CT010","article-title":"Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors","volume":"85","author":"Xu","year":"","journal-title":"Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"S2053","DOI":"10.1016\/j.annonc.2025.10.1234","article-title":"A phase I clinical study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HDM2020 (FGFR2b-ADC) in patients with advanced solid tumors","volume":"36","author":"Xu","year":"","journal-title":"Ann. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan","year":"2025","journal-title":"Mol. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci. Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2025.43.16_suppl.3034","article-title":"Efficacy and safety of XNW27011, a claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with claudin 18.2 positive gastric\/gastroesophageal junction cancer: results from ongoing phase I\/II study","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/JCO.2023.41.4_suppl.397","article-title":"A phase I\/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1016\/j.cell.2025.08.033","article-title":"Epithelial-mesenchymal transition","volume":"188","author":"Zhang","year":"2025","journal-title":"Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2026.44.2_suppl.374","article-title":"Phase 1 study of LB1908, an autologous claudin 18.2-targeted CAR-T cell product, in subjects with advanced gastroesophageal adenocarcinoma","volume":"44","author":"Zhen","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1158\/1538-7445.AM2026-5402","article-title":"Engineering and development of a novel bispecific ADC targeting EGFR and FGFR2b","volume":"86","author":"Zhu","year":"2026","journal-title":"Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrm.2016.80","article-title":"Tight junctions: from simple barriers to multifunctional molecular gates","volume":"17","author":"Zihni","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1927389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:47:43Z","timestamp":1790336863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1927389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":114,"alternative-id":["10.3389\/fmmed.2026.1927389"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2026.1927389","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1927389"}}